Lawsuit Alert: Hagens Berman law firm warns Inspire Medical Systems (INSP) investors about a pending securities class action lawsuit for concealing operational failures, urging investors to contact attorneys by January 5, 2026, to protect their rights.
Stock Collapse: Inspire Medical Systems faced a catastrophic stock drop of $42.04 per share, translating to a 32.4% decline in value, after slashing its 2025 EPS guidance by over 80% due to failure in launching the Inspire V device as promised.
Operational Issues: The lawsuit highlights that Inspire Medical failed to implement necessary Medicare claims processing software updates on time, preventing implant centers from billing for procedures and severely hindering early adoption and revenue generation.
Excess Inventory: The presence of significant surplus inventory of the older Inspire IV device among customers and treatment centers negatively impacted demand for the new Inspire V product, necessitating an inventory “burn down” that exacerbated financial pressures.
INSP
$118.27+Infinity%1D
Analyst Views on INSP
Wall Street analysts forecast INSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INSP is 115.58 USD with a low forecast of 82.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast INSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INSP is 115.58 USD with a low forecast of 82.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
5 Hold
0 Sell
Moderate Buy
Current: 115.510
Low
82.00
Averages
115.58
High
180.00
Current: 115.510
Low
82.00
Averages
115.58
High
180.00
Mizuho
Outperform
maintain
$110 -> $130
2025-12-17
New
Reason
Mizuho
Price Target
$110 -> $130
2025-12-17
New
maintain
Outperform
Reason
Mizuho raised the firm's price target on Inspire Medical to $130 from $110 and keeps an Outperform rating on the shares. The firm adjusted targets in the medical devices and diagnostics group as part of its 2026 outlook. Despite stock valuations trending back toward two-year highs post the Q3 reports, there is potential for further multiple expansion "under a scenario where the dual AI + Cryptocurrency mega-trades remain influx with Healthcare positioned as the top defensive sector," the analyst tells investors in a research note.
JPMorgan
Neutral
maintain
$82 -> $118
2025-12-16
New
Reason
JPMorgan
Price Target
$82 -> $118
2025-12-16
New
maintain
Neutral
Reason
JPMorgan raised the firm's price target on Inspire Medical to $118 from $82 and keeps a Neutral rating on the shares. The firm updated the company's model to reflect its increased reimbursement rates.
Oppenheimer
Suraj Kalia
Perform
to
Outperform
upgrade
$175
2025-12-08
Reason
Oppenheimer
Suraj Kalia
Price Target
$175
2025-12-08
upgrade
Perform
to
Outperform
Reason
As previously reported, Oppenheimer analyst Suraj Kalia upgraded Inspire Medical to Outperform from Perform with a $175 price target. The firm believes CMS has erred on mapping HGNS facility rate to higher levels, violating its own cost input protocol for rate-setting. Company commentary also suggests ASP increases now in play, Oppenheimer adds. If ASP's are raised about 20%-40%, revenues increase about 30%-50%, gross margins 200-350 bps, and EPS increases to about $6.50-$11.50.
Oppenheimer
Oppenheimer
Perform -> Outperform
upgrade
$175
2025-12-08
Reason
Oppenheimer
Oppenheimer
Price Target
$175
2025-12-08
upgrade
Perform -> Outperform
Reason
Oppenheimer upgraded Inspire Medical to Outperform from Perform with a $175 price target.
About INSP
Inspire Medical Systems, Inc. is a medical technology company. The Company is focused on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. It has developed a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
